|1.||Harper, Diane M: 6 articles (01/2011 - 09/2008)|
|2.||Schiller, John T: 4 articles (06/2014 - 08/2008)|
|3.||Dubin, Gary: 3 articles (11/2014 - 01/2009)|
|4.||Kim, Young Bong: 2 articles (06/2015 - 03/2011)|
|5.||Oh, Yu-Kyoung: 2 articles (06/2015 - 03/2011)|
|6.||Taylor, Sylvia: 2 articles (11/2014 - 01/2014)|
|7.||Roden, Richard B S: 2 articles (06/2014 - 02/2013)|
|8.||Giannini, Sandra L: 2 articles (05/2014 - 11/2008)|
|9.||Pinto, Ligia A: 2 articles (12/2012 - 11/2008)|
|10.||Hildesheim, Allan: 2 articles (12/2012 - 08/2008)|
10/01/2011 - "Herrero and colleagues show that in a phase III randomized trial in Guanacaste, Costa Rica, the use of a human papillomavirus type 16 (HPV16) and HPV18 ASO4-adjuvanted vaccine (Cervarix) resulted in complete efficacy against 12-month persistent HPV16 and HPV18 infections and partial protection against HPV31, 33, and 45 in HPV-naïve young women ages 18 to 25."
08/01/2011 - "The HPV-16/18 AS04-adjuvanted vaccine Cervarix has shown a high level of protection against HPV-16/18 infections and associated cervical lesions. "
01/01/2009 - "The human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine (Cervarix) has been shown to be well-tolerated and immunogenic in females aged 10 to 55 years, and up to 100% effective for the prevention of HPV-16/18 infection and associated precancerous cervical lesions in females aged 15 to 25 years. "
11/20/2012 - "Cervarix(®) protected against vaccine-targeted anal infections in women in an end of study evaluation. "
04/01/2013 - "Cervarix vaccine was included in the National Immunization Program of Argentina in 2011 but data about the local distribution of human papillomavirus (HPV) infection in women exposed to the virus are scarce. "
11/01/2009 - "HPV-16/18 AS04-adjuvanted vaccine (Cervarix; GlaxoSmithKline Biologicals, Rixensart, Belgium) has demonstrated type-specific protection against the five most frequent cancer-causing types (16, 18, 31, 33, and 45) that are responsible for 82% of invasive cervical cancers globally. "
01/01/2014 - "We developed a dynamic compartmental model to assess the impact of HPV Universal Mass Vaccination with Cervarix(®), which offers protection against HPV16/18 and cross-protection against other cancer-causing types, using up-to-date efficacy data. "
11/01/2009 - "Protection offered by Cervarix against nonvaccine types (mainly 31, 33, and 45) might potentially allow for 11%-16% additional protection against cervical cancers, compared to a vaccine only offering protection against HPV-16/18. "
11/01/2008 - "Here, we compare both the direct ELISA and the single epitope-based inhibition ELISA with the pseudovirion-based neutralization assay (PBNA) for HPV-16/18 antibody responses in vaccinated women enrolled in trials of Cervarix, GSK's cervical cancer vaccine. "
12/01/2012 - "The other (Cervarix(®)) contains types 16 and 18, targeting cervical cancer alone, but also has a degree of cross-protection against types 31 and 45, which could significantly increase the level of protection. "
01/01/2011 - "With additional cross-protection to HPV 31, 33, and 45 and protection against HPV 16 and 18 lasting at least 9.4 years, Cervarix may reduce adenocarcinomas in screened populations by more than 90%. "
12/01/2009 - "Cervarix is effective against HPV-16, -18, -31, -33 and -45, the five most common cancer-causing types, including most causes of adenocarcinoma for which we cannot screen adequately. "
11/01/2009 - "Cervarix has demonstrated efficacy against HPV-45, which is the third most common HPV type in cervical cancer and adenocarcinoma. "
|4.||Condylomata Acuminata (Genital Wart)
07/01/2008 - "(Whitehouse Station, NJ) and Cervarix, manufactured by GlaxoSmithKline (GSK, Philadelphia) holds tremendous promise for the developing countries in decreasing the burden of HPV infection and its sequelae, such as cervical cancer, genital warts and anogenital cancers. "
12/01/2007 - "The two new HPV vaccines (Gardasil quadrivalent and Cervarix bivalent 16,11) are both effective against HPV types 16 and 18, which are responsible for 70% of cervical cancers, and the quadrivalent vaccine is effective against HPV 6 and 11, responsible for genital warts. "
09/07/2012 - "Currently there are two HPV vaccines registered in South Africa: the bivalent vaccine Cervarix, containing VLP antigens for oncogenic HPV types 16 and 18; and the quadrivalent vaccine Gardasil, containing VLP antigens for HPV types 16 and 18, as well as non-oncogenic HPV types 6 and 11, which are the most common types causing genital warts. "
02/01/2011 - "The newly introduced vaccines that prevent HPV infections are the quadrivalent vaccine (Gardasil), which prevents genital warts and cervical cancer, and the bivalent vaccine (Cervarix), which prevents cervical cancer only. "
|5.||Cervical Intraepithelial Neoplasia
11/01/2009 - "Final results of a large phase 3 trial recently showed Cervarix substantially reduced the overall burden of cervical precancerous lesions (cervical intraepithelial neoplasia 2+) by 70.2% in an HPV-naïve population approximating young girls prior to sexual debut, the target of most current vaccination programs. "
07/01/2009 - "Cervarix is a recombinant human papillomavirus (HPV)-16 and -18 L1 virus-like-particle (VLP) AS04-adjuvanted vaccine designed to protect against cervical intraepithelial neoplasia and cervical cancer caused by the HPV types 16 and 18. "
07/01/2010 - "At this time, protection against cervical intraepithelial neoplasia grade 2/3 (CIN 2/3) is 5 years for Gardasil and 8.4 years for Cervarix. "
01/01/2014 - "The mean odds ratio (OR) and 95% confidence interval (CI) for the association between Cervarix, Gardasil and HPV-16 monovalent vaccine and HPV-associated cervical intraepithelial neoplasia grade 3 or worse was 0·90 (95% CI: 0·56, 1·44). "
12/01/2009 - "Both Cervarix and Gardasil provided more than 90% efficacy in preventing cervical intraepithelial neoplasia grade 2+ (CIN 2+) disease caused by HPV 16 and 18 in women 16-26 years who were seronegative and PCR-negative for HPV 16 and 18 at baseline. "
|1.||type 6,11,16,18 human papillomavirus vaccine L1 (Gardasil)
|2.||Papillomavirus Vaccines (HPV Vaccines)
|4.||DNA (Deoxyribonucleic Acid)
|7.||Herpes Zoster Vaccine
|8.||Leukocyte L1 Antigen Complex (Calgranulin)
|9.||Capsid Proteins (Capsid Protein)
|10.||Hepatitis A Vaccines (Hepatitis A Vaccine)